Sale by Sean Power of 73647 shares of TG Therapeutics

TGTX Stock  USD 32.20  1.25  4.04%   
Slightly above 71 percent of all TG Therapeutics' investors are curious in acquiring. The analysis of the overall investor sentiment regarding TG Therapeutics suggests that a large number of traders are confidant. TG Therapeutics' investing sentiment can be driven by a variety of factors including economic data, TG Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Tg Therapeutics Inc officer. General open market or private sale of non-derivative or derivative security

Read at macroaxis.com
TGTX insider trading alert for sale of common stock by Sean Power, Chief Financial Officer, on 5th of June 2023. This event was filed by Tg Therapeutics Inc with SEC on 2023-06-05. Statement of changes in beneficial ownership - SEC Form 4. Sean Power currently serves as cfo, treasurer, corporate secretary of TG Therapeutics

Cash Flow Correlation

TG Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the TG Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

TG Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards TG Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

TG Therapeutics Fundamental Analysis

We analyze TG Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TG Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TG Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Number Of Shares Shorted

Number Of Shares Shorted Comparative Analysis

TG Therapeutics is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

TG Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with TG Therapeutics stock to make a market-neutral strategy. Peer analysis of TG Therapeutics could also be used in its relative valuation, which is a method of valuing TG Therapeutics by comparing valuation metrics with similar companies.

Peers

TG Therapeutics Related Equities

BTAIBioXcel Therapeutics   6.25   
0%
82.0%
MDGLMadrigal Pharmaceuticals   5.12   
0%
67.0%
AKROAkero Therapeutics   3.31   
0%
43.0%
VKTXViking Therapeutics   1.83   
0%
24.0%
EXELExelixis   1.16   
15.0%
0%
TERNTerns Pharmaceuticals   3.14   
41.0%
0%
XFORX4 Pharmaceuticals   4.69   
62.0%
0%
PDSBPDS Biotechnology   5.71   
75.0%
0%
HEPAHepion Pharmaceuticals   7.55   
100.0%
0%

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.